Enliven Therapeutics, a clinical-stage biotech born in Boulder and now run by former Roche/Genentech commercial chief Rick Fair, has packed its bags for the Bay Area and lined up roughly $400 million in fresh funding to fuel its lead leukemia drug. The relocation and the cash hit just as the company gets ready to push ELVN-001 into a pivotal Phase 3 trial for chronic myeloid leukemia.
Company prices roughly $400 million
According to Enliven Therapeutics, the company priced an upsized public offering last Thursday that is expected to generate about $400 million in gross proceeds. The offering, a mix of common stock and pre-funded warrants priced at $37.50 per share, was expected to close on or about June 15, 2026, subject to customary closing conditions.
Burlingame lease formalizes Bay Area shift
Enliven's SEC filings show the company entered into a Bay Area lease in April 2026 for roughly 7,200 square feet in Burlingame, with a lease term beginning June 1. The SEC 10-Q pegs monthly base rent at about $41,000 and notes that the Bay Area lease had not commenced as of March 31.
Ex-Genentech commercial chief at the wheel
Rick Fair, who joined Enliven as CEO in December 2025, brings more than 25 years of product development and commercialization experience, including leadership roles at Roche/Genentech and a recent stint as Bellicum Pharmaceuticals' CEO. The company's SEC disclosures describe Fair's background overseeing global oncology and hematology portfolios and include his brief statement that he is very excited to join Enliven as CEO. For additional background on his appointment and résumé, see the company's SEC filings.
Phase 1 data fuels the push to Phase 3
Enliven has reported encouraging Phase 1b results for ELVN-001, saying the drug delivered strong major-molecular-response rates in a heavily pretreated chronic myeloid leukemia population while maintaining a favorable tolerability profile. In a January company release, Enliven highlighted 24-week cumulative MMR figures and said it is preparing regulatory interactions with the FDA ahead of a planned initiation of the ENABLE-2 Phase 3 trial in the second half of 2026. That update is summarized by Enliven Therapeutics in its investor materials.
Local angle and why it matters
For Bay Area biotech watchers, the move brings a late-stage hematology program closer to the region's deeper commercialization, investment and talent pools, factors that tend to matter when a company shifts from pure clinical work to serious market planning. The relocation and financing were also reported by the Denver Business Journal, which framed the story as a Boulder startup heading out after a major capital raise.
What's next
Assuming the offering closes and regulatory talks proceed as outlined, Enliven expects to advance ELVN-001 into a pivotal Phase 3 study in the back half of 2026, a timeline the company has already signaled in investor updates. If the drug continues to look like it has in early testing, and the new capital provides the runway Enliven is planning for, the company will likely ramp up commercial planning and hiring out of its new Bay Area base as it prepares for later-stage development.
